# major depressive disorder FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/major-depressive-disorder

> 29 upcoming FDA catalysts in major depressive disorder: azetukalner (XENE) on Dec 2026 (topline data readout); ALTO-300 (ANRO) on December 2026 (primary completion); ALTO-300 (ANRO) on Dec 2026 to Mar 2027 (topline data readout); azetukalner (XENE) on January 2027 (primary completion); and 25 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Apr 2024 | [Osavampator topline data readout](https://sec-api.dev/pdufa/osavampator) | NBIX | major depressive disorder | completed, positive | "In April 2024, we announced positive top-line data from the Phase 2 SAVITRI™ study of osavampator in adults with major depressive disorder." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/914475/000091447525000037/nbix-20241231.htm)) |
| July 25, 2025 | [NBI-1070770 primary completion](https://sec-api.dev/pdufa/nbi-1070770) | NBIX | Major Depressive Disorder | completed | "NCT06267846 (A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-25 (ACTUAL); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06267846)) |
| September 2025 | [Psilocybin primary completion](https://sec-api.dev/pdufa/psilocybin) | CMPS | Major Depressive Disorder | delayed | "NCT05733546 (A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-09 (ESTIMATED); Lead Sponsor COMPASS Pathways." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05733546)) |
| November 7, 2025 | [BHV-7000 primary completion](https://sec-api.dev/pdufa/bhv-7000) | BHVN | Major Depressive Disorder | completed | "NCT06419608 (Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-07 (ACTUAL); Lead Sponsor Biohaven Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06419608)) |
| March 18, 2026 | [BHV-7000 primary completion](https://sec-api.dev/pdufa/bhv-7000) | BHVN | Major Depressive Disorder | completed | "NCT06423781 (Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-03-18 (ACTUAL); Lead Sponsor Biohaven Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06423781)) |
| May 4, 2026 | [Navacaprant primary completion](https://sec-api.dev/pdufa/navacaprant) | NMRA | Major Depressive Disorder | completed | "NCT06058039 (Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-05-04 (ACTUAL); Lead Sponsor Neumora Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06058039)) |
| May 6, 2026 | [Navacaprant primary completion](https://sec-api.dev/pdufa/navacaprant) | NMRA | Major Depressive Disorder | completed | "NCT06058013 (Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-05-06 (ACTUAL); Lead Sponsor Neumora Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06058013)) |
| May 20, 2026 | [Lysergide tartrate primary completion](https://sec-api.dev/pdufa/lysergide) | DFTX | Major Depressive Disorder | completed | "NCT06941844 (A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-05-20 (ACTUAL); Lead Sponsor Definium Therapeutics US, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06941844)) |
| July 27, 2026 | [GM-2505 primary completion](https://sec-api.dev/pdufa/gm-2505) | ABBV | Major Depressive Disorder | completed | "NCT06236880 (A Phase 2a Study to Evaluate the Safety and Tolerability of GM-2505 in Patients With MDD): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-07-27 (ACTUAL); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06236880)) |
| August 17, 2026 | [Navacaprant primary completion](https://sec-api.dev/pdufa/navacaprant) | NMRA | Major Depressive Disorder | withdrawn | "NCT06029439 (Study to Assess the Safety and Effectiveness of NMRA-335140-501): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-08-17 (ACTUAL); Lead Sponsor Neumora Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06029439)) |
| October 2026 | [Azetukalner primary completion](https://sec-api.dev/pdufa/azetukalner) | XENE | Major Depressive Disorder | delayed | "NCT06775379 (A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10 (ESTIMATED); Lead Sponsor Xenon Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06775379)) |
| Dec 2026 | [Azetukalner topline data readout](https://sec-api.dev/pdufa/azetukalner) | XENE | Major Depressive Disorder | scheduled | "Enrollment in Phase 3 X-NOVA2 study of azetukalner in MDD completed with topline data readout now expected in December 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1582313/000119312526453521/xene-ex99_1.htm)) |
| December 2026 | [ALTO-300 primary completion](https://sec-api.dev/pdufa/alto-300) | ANRO | Major Depressive Disorder | scheduled | "NCT05922878 (Study of ALTO-300 in MDD): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Alto Neuroscience." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05922878)) |
| Dec 2026 to Mar 2027 | [ALTO-300 topline data readout](https://sec-api.dev/pdufa/alto-300) | ANRO | Major Depressive Disorder | scheduled | "NCT05922878 (Study of ALTO-300 in MDD): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Alto Neuroscience." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05922878)) |
| January 2027 | [Azetukalner primary completion](https://sec-api.dev/pdufa/azetukalner) | XENE | Major Depressive Disorder | scheduled | "NCT06922110 (An Open-Label Study of Azetukalner in Major Depressive Disorder): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01 (ESTIMATED); Lead Sponsor Xenon Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06922110)) |
| Jan to Apr 2027 | [Azetukalner topline data readout](https://sec-api.dev/pdufa/azetukalner) | XENE | Major Depressive Disorder | scheduled | "NCT06922110 (An Open-Label Study of Azetukalner in Major Depressive Disorder): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01 (ESTIMATED); Lead Sponsor Xenon Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06922110)) |
| Apr to Jul 2027 | [Caplyta (lumateperone tosylate) topline data readout](https://sec-api.dev/pdufa/lumateperone) | JNJ | Major Depressive Disorder | scheduled | "NCT05850689 (Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-04-05 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05850689)) |
| April 2027 | [Caplyta (lumateperone tosylate) primary completion](https://sec-api.dev/pdufa/lumateperone) | JNJ | Major Depressive Disorder | scheduled | "NCT05850689 (Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-04-05 (ESTIMATED); Lead Sponsor Intra-Cellular Therapies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05850689)) |
| May 2027 | [Azetukalner primary completion](https://sec-api.dev/pdufa/azetukalner) | XENE | Major Depressive Disorder | scheduled | "NCT07076407 (A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Xenon Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07076407)) |
| May to Aug 2027 | [Azetukalner topline data readout](https://sec-api.dev/pdufa/azetukalner) | XENE | Major Depressive Disorder | scheduled | "NCT07076407 (A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05 (ESTIMATED); Lead Sponsor Xenon Pharmaceuticals Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07076407)) |
| July 2027 | [NBI-1065845 primary completion](https://sec-api.dev/pdufa/nbi-1065845) | NBIX | Major Depressive Disorder | scheduled | "NCT06786624 (Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06786624)) |
| Jul to Oct 2027 | [NBI-1065845 topline data readout](https://sec-api.dev/pdufa/nbi-1065845) | NBIX | Major Depressive Disorder | scheduled | "NCT06786624 (Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06786624)) |
| July 2027 | [NBI-1065845 primary completion](https://sec-api.dev/pdufa/nbi-1065845) | NBIX | Major Depressive Disorder | scheduled | "NCT06911112 (NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06911112)) |
| Jul to Oct 2027 | [NBI-1065845 topline data readout](https://sec-api.dev/pdufa/nbi-1065845) | NBIX | Major Depressive Disorder | scheduled | "NCT06911112 (NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06911112)) |
| July 2027 | [NBI-1065845 primary completion](https://sec-api.dev/pdufa/nbi-1065845) | NBIX | Major Depressive Disorder | scheduled | "NCT06963021 (NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06963021)) |
| Jul to Oct 2027 | [NBI-1065845 topline data readout](https://sec-api.dev/pdufa/nbi-1065845) | NBIX | Major Depressive Disorder | scheduled | "NCT06963021 (NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06963021)) |
| September 2027 | [Icalcaprant primary completion](https://sec-api.dev/pdufa/icalcaprant) | ABBV | Major Depressive Disorder | scheduled | "NCT07276997 (A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07276997)) |
| Sep to Dec 2027 | [Icalcaprant topline data readout](https://sec-api.dev/pdufa/icalcaprant) | ABBV | Major Depressive Disorder | scheduled | "NCT07276997 (A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07276997)) |
| September 2027 | [Lysergide tartrate primary completion](https://sec-api.dev/pdufa/lysergide) | DFTX | Major Depressive Disorder | scheduled | "NCT07592689 (A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Definium Therapeutics US, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07592689)) |
| Sep to Dec 2027 | [Lysergide tartrate topline data readout](https://sec-api.dev/pdufa/lysergide) | DFTX | Major Depressive Disorder | scheduled | "NCT07592689 (A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09 (ESTIMATED); Lead Sponsor Definium Therapeutics US, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07592689)) |
| May 2028 | [Brenipatide primary completion](https://sec-api.dev/pdufa/brenipatide) | LLY | Major Depressive Disorder | scheduled | "NCT07928245 (A Study of Brenipatide in Participants With Major Depressive Disorder): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07928245)) |
| May to Aug 2028 | [Brenipatide topline data readout](https://sec-api.dev/pdufa/brenipatide) | LLY | Major Depressive Disorder | scheduled | "NCT07928245 (A Study of Brenipatide in Participants With Major Depressive Disorder): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07928245)) |
| July 2028 | [Osavampator primary completion](https://sec-api.dev/pdufa/osavampator) | NBIX | Major Depressive Disorder | scheduled | "NCT07196501 (A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07196501)) |
| Jul to Oct 2028 | [Osavampator topline data readout](https://sec-api.dev/pdufa/osavampator) | NBIX | Major Depressive Disorder | scheduled | "NCT07196501 (A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07196501)) |
| Nov 2028 to Feb 2029 | [Evifacotrep topline data readout](https://sec-api.dev/pdufa/evifacotrep) | BMY | Major Depressive Disorder | scheduled | "NCT07772531 (A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-11-06 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07772531)) |
| November 2028 | [Evifacotrep primary completion](https://sec-api.dev/pdufa/evifacotrep) | BMY | Major Depressive Disorder | scheduled | "NCT07772531 (A Study to Evaluate BMS-986511 in Adults With Major Depressive Disorder): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-11-06 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07772531)) |
| May 2029 | [NBI-1065845 primary completion](https://sec-api.dev/pdufa/nbi-1065845) | NBIX | Major Depressive Disorder | scheduled | "NCT06966401 (Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-05 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06966401)) |
| May to Aug 2029 | [NBI-1065845 topline data readout](https://sec-api.dev/pdufa/nbi-1065845) | NBIX | Major Depressive Disorder | scheduled | "NCT06966401 (Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-05 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06966401)) |
| Sep to Dec 2029 | [Trintellix (vortioxetine hydrobromide) topline data readout](https://sec-api.dev/pdufa/vortioxetine) | TAK | Major Depressive Disorder | scheduled | "NCT07204314 (A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-30 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07204314)) |
| September 2029 | [Trintellix (vortioxetine hydrobromide) primary completion](https://sec-api.dev/pdufa/vortioxetine) | TAK | Major Depressive Disorder | scheduled | "NCT07204314 (A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-30 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07204314)) |

## Drugs

- [Osavampator](https://sec-api.dev/pdufa/osavampator) (NBIX)
- [NBI-1070770](https://sec-api.dev/pdufa/nbi-1070770) (NBIX)
- [Psilocybin](https://sec-api.dev/pdufa/psilocybin) (CMPS)
- [BHV-7000](https://sec-api.dev/pdufa/bhv-7000) (BHVN)
- [Navacaprant](https://sec-api.dev/pdufa/navacaprant) (NMRA)
- [Lysergide tartrate](https://sec-api.dev/pdufa/lysergide) (DFTX)
- [GM-2505](https://sec-api.dev/pdufa/gm-2505) (ABBV)
- [Azetukalner](https://sec-api.dev/pdufa/azetukalner) (XENE)
- [ALTO-300](https://sec-api.dev/pdufa/alto-300) (ANRO)
- [Caplyta (lumateperone tosylate)](https://sec-api.dev/pdufa/lumateperone) (JNJ)
- [NBI-1065845](https://sec-api.dev/pdufa/nbi-1065845) (NBIX)
- [Icalcaprant](https://sec-api.dev/pdufa/icalcaprant) (ABBV)
- [Brenipatide](https://sec-api.dev/pdufa/brenipatide) (LLY)
- [Evifacotrep](https://sec-api.dev/pdufa/evifacotrep) (BMY)
- [Trintellix (vortioxetine hydrobromide)](https://sec-api.dev/pdufa/vortioxetine) (TAK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/major-depressive-disorder.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "major depressive disorder FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/major-depressive-disorder

```bibtex
@misc{secapidev_indications_major_depressive_disorder_20261116,
  title        = {major depressive disorder FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/major-depressive-disorder}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_major_depressive_disorder_20261116","title":"major depressive disorder FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/major-depressive-disorder","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
